# Empagliflozin as a Novel Therapy in Refractory Ascites

> **NCT05430243** · PHASE2,PHASE3 · COMPLETED · sponsor: **Alexandria University** · enrollment: 42 (actual)

## Conditions studied

- Ascites Hepatic

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Diuretics

## Key facts

- **NCT ID:** NCT05430243
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2022-11-12
- **Final completion:** 2022-11-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430243, "Empagliflozin as a Novel Therapy in Refractory Ascites". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05430243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*